Choroideremia (CHM) is an X-linked retinal degenerative disease resulting from a lack of functional Rab Escort Protein-1 (REP-1). As a first step in developing gene-based therapies for this disease, we evaluated the feasibility of delivering functional REP-1 to defective lymphocytes and fibroblasts isolated from individuals with CHM. A recombinant adenovirus delivering the full-length human cDNA encoding REP-1 under the control of a cytomegalovirus promoter was generated. Adenovirus-mediated delivery of REP-1 rescued the defective cells as assessed through protein and enzymatic assays. Ultimately, it may be possible to use virusmediated delivery of REP-1 to evaluate disease intervention in vivo.
Introduction
Choroideremia or tapeto-choroidal dystrophy (CHM; MIM # 303100, (McKusick, 1994) ) is a common form of X-linked recessive retinal degeneration. It is one of the few hereditary retinal degenerations that can be specifically identified by clinical examination of the retina (Sorsby, Franceshetti, Joseph, & Davey, 1952) . Mottled areas of pigmentation are apparent in fundus examination in affected children and female carriers. By adolescence, affected males display scalloped areas of confluent loss of retinal pigment epithelium (RPE) and choriocapillaris. These changes are readily apparent on standard ophthalmoscopy and can be confirmed by pathognomic findings on fluorescein angiography. The changes often result in total blindness by the third or fourth decade. Heterozygous females, in contrast, have no or milder symptoms, probably dependent on the degree of X chromosome inactivation. Female carriers can, however, be reliably identified by ophthalmoscopy (Karna, 1986) .
At present, there is neither a treatment nor a cure for CHM. There are several reasons, however, why this disease may be a good candidate for gene therapy studies: (1) The complete human cDNA implicated in CHM has been identified and cloned. This gene encodes Rab Escort Protein 1 (REP-1) (van Bokhoven et al., 1994a) . REP-1 is a protein which escorts the Rab proteins during and after their prenylation to intracellular membranes (Alexandrov, Horiuchi, Steele-Mortimer, Seabra, & Zerial, 1994; Andres et al., 1993; Seabra, Brown, Slaughter, Sudhof, & Goldstein, 1992) . This protein also plays an important role in the prenylation reaction itself in retinal tissues as it is indispensable for the activity of Rab geranylgeranyl transferase (Rab GGTase); (2) The disease is caused by a lack of a functional gene product. At least 15 different small mutations (i.e., involving only 1-4 nucleotides) have been identified so far in the gene encoding REP-1. All of the REP-1 mutations identified so far in affected individuals are predicted to lead to premature stops during translation and to result either in a protein truncated at the carboxy-terminus or in no protein at all (Sankila, Tolvanen, van den Hurk, Cremers, & de la Chapelle, 1992; Schwartz, Rosenberg, van den Hurk, van depol, & Cremers, 1993; van Bokhoven et al., 1994b; van den Hurk et al., 1992) ; (3) CHM is one of the few retinal degenerative diseases in which the defective gene can be identified upon clinical examination. Thus, a large population of affected individuals with this particular gene defect is already available; (4) While carriers of this disease are identifiable clinically, they suffer minimal symptoms. Thus, addition of the wild type version of REP-1 should result in rescue of the diseased cells; and (5) REP-1 is normally expressed in other tissues besides retinal cells. Such tissues (lymphocytes, fibroblasts, for example) from individuals with CHM appear normal otherwise, probably due to the ability of a second REP protein, REP-2, to carry out the necessary functions in these cells (Cremers, Armstrong, Seabra, Brown, & Goldstein, 1994; Seabra, 1996) . Lymphocytes and fibroblasts, unlike retinal tissue, can be harvested noninvasively and cultured for extended periods of time. Therefore, they are well-suited for in vitro rescue studies.
In the present study, we generated and purified a recombinant adenovirus carrying the cDNA encoding human REP-1 and tested the ability of this virus to rescue fibroblasts and transformed lymphocytes from individuals affected with CHM. Rescue was assessed through protein studies (Western blots and immunofluorescence) and functional assay.
Materials and methods

Human tissues
Samples from affected individuals, carriers and unaffected individuals from two different families with CHM were used. Samples were obtained by venipuncture and/ or skin biopsy after informed consent had been obtained. In the first family, a premature stop codon (Arg555 ! stop) mutation leads to a carboxy-terminal truncation of 99 amino acids (Fujita, Skolnick, Pastkis, Yang Fen, & Swaroop, 1995) . Cells from an affected individual in this family are identified here as CPF1. In the second family, there is an X chromosome deletion of 250 Kb in the CHM locus (Cremers et al., 1990a (van Bokhoven et al., 1994b) ) after AflIII digestion. An initiation codon was introduced via polymerase chain reaction (PCR; using sense primer: 5 0 -ATGGCGGA-TACTCTCCCTTCGG-3 0 and antisense primer: 5 0 -AC-CTGTTCCACTCGTCCTTCTC-3 0 ) and the full length cDNA was cloned into the TA cloning vector (Invitrogen, Carlsbad, CA). The 2.5 kb cDNA was inserted into pBluescript II KSðþÞ (Stratagene) and then subsequently cut with Sma1 and Kpn1 and cloned into EcoRV/Kpn1-cut Ad.CMVLink1 (provided by J. Wilson), which placed REP-1 under control of the cytomegalovirus (CMV) enhancer/promoter sequence and the SV40 poly(A) sequence ( Fig. 1) (Bennett et al., 1996) .
The recombinant adenovirus Ad.REP-1 was generated through homologous recombination with the pAd.CMV-Link.1-derived plasmids and Ad5 strain dl7001. This strain is deleted of E1 and the majority of the E3 region (3.2 kb). Recombinants were obtained in 293 cells and were identified by Southern blot analysis. The recombinant adenovirus was amplified, purified, and titered to 10 12 particles/ml as described (Bennett, Zeng, Gupta, & Maguire, 2000) . Adenoviruses were screened for the presence of contaminating wild type virus as described (Bennett et al., 1998) . No contaminants were detected. The same stocks of adenoviruses were used for all experiments. All manipulations of adenoviral vectors were done according to institutional and national biosafety restrictions.
Infection of fibroblasts and transformed lymphocytes with Ad.REP-1
Fibroblasts and lymphoblasts from individuals with CHM and their relatives were plated in 100 mm culture plates in an enriched media as described above. The cells were grown till they reached 70% confluency. At that time, the percentage of serum was reduced from 10% to 2% to increase the efficiency of infection with Ad.REP-1. Two microlitres of experimental or control virus were added to the 100 mm plates providing exposure of 10 plaque-forming units per cell. Cells were maintained at 37°C for 25-40 h. The cells were then harvested for Western blots or immunostaining.
Protein studies 2.4.1. Western analysis
Western analysis was performed to evaluate presence of the REP-1 protein. Frozen cell pellets were thawed, resuspended in three volumes of lysis buffer (50 mM Tris-Cl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 5 mM DTT, 0.5 M phenylmethylsulfonyl fluoride, 5 lg/ml pepstatin, 5 lg/ml aprotinin and 5 lg/ml leupeptin) and mechanically disrupted by serial passages through a 21-gauge needle. The lysate was spun at 100; 000 Â g for 1 h. The pellet was discarded and the supernatant loaded on a continuous 8% SDS-PAGE gel. Separated proteins were transferred to PVDF membrane using a Hoeffer transfer apparatus (2 h at 500 mA). The membranes were allowed to dry and were blocked for 1 h with 5% skimmed milk in incubation buffer (phosphate-buffered saline (PBS), 0.2% Tween-20). The membranes were then incubated with either 2F1 (1:1000) or J905 (1:5000) antibodies diluted in incubation buffer. J905 is a rabbit polyclonal antibody directed against recombinant rat REP-1 (Forsythe et al., 1997) . J905 recognizes both human REP-1 (CHM) and REP-2 (CHML) proteins. 2F1 is a mouse monoclonal antibody which recognizes human REP-1 only (Alexandrov et al., 1994) . The immunogen used to generate 2F1 was a fusion protein consisting of glutathione-S-transferase fused to the Cterminal 415 amino acids of human REP-1 (Alexandrov et al., 1994; MacDonald, Mah, Ho, Lewis, & Seabra, 1998) . After washing, blots were incubated with the secondary antibody peroxidase-labeled goat anti-rabbit (for J905, Dako) or sheep anti-mouse antibody (for 2F1, Amersham) diluted 1:10,000 in the incubation buffer and developed using the Supersignal West Pico Chemiluminescent Substrate (Pierce Chemical Co., Rockford, IL) according to the manufacturerÕs directions.
Immunofluorescent staining of fibroblasts/lymphoblasts
Cells were plated in six-well plates containing sterile 22 mm 2 coverslips, grown until they reached 70% confluency and infected as describe above. Lymphoblasts were infected with Ad.Rep-1 in 2% FBS containing DMEM or RPMI at an MOI of 30 and cultured another 24-40 h. Control cells were infected with Ad.LacZ. At the end of infection, the media was aspirated, cells washed with PBS, and fixed for 10 min with 4% paraformaldehyde. After three washes, the cells were permeabilized with 0.2% Triton in PBS, blocked with 3% BSA in PBS for 2 h and incubated with primary antibody (J905 or 2F1) for 2 h. After washing, secondary antibody (FITC labeled goat anti-rabbit for J905 and FITC-labeled goat anti-mouse for 2F1; Jackson Immunoresearch, diluted 1:1000) was applied to the cells for an hour. After washing, cells were counterstained with Hoechst stain and mounted on slides using citifluor (Ted Pella Inc.). Fluorescence was observed under a Leica DMRE Microscope (Leica Microsystems, Inc.; Deerfield, IL) equipped with FITC and rhodamine filters. Images were acquired digitally using OpenLab software (Improvision).
Prenylation assay
Assays for the ability of the transgenic REP-1 protein to assist in the prenylation reaction were performed as described by Seabra and James (1999) . Briefly, experimental and control fibroblasts and lymphoblasts infected with Ad.REP-1 were harvested 24-40 h after infection and stored at )80°C until use. Reactions were performed using tritiated all-trans-geranylgeranyl pyrophosphate (Dupont-New England Nuclear) as a prenyl donor, recombinant Rab geranylgeranyl transferase and increasing concentration of lysate from the infected cells. Recombinant REP-1 was used in place of cell lysate as a positive control. Incorporation of radiolabeled prenyl groups into protein was determined by ethanol/ HCl precipitation and collection of precipitated protein onto glass-fiber filters by vacuum filtration. Reactions were performed in duplicate.
Results
REP-1 (but not REP-2) is absent from the cells harvested from individuals with Choroideremia
Western analysis using a monoclonal a-REP-1 antibody (2F1) revealed a single protein of 95 kDa in carriers but not in affected individuals (data not shown and Fig. 3 ). A truncated protein (which, if present, was predicted to be $84 kDa for CPF1) was not detected. REP-2, detected with antibody J905, was present in both affected individuals and carriers ( Fig. 3 and data not shown).
Ad.REP-1 infection of cultured cells from individuals with CHM results in immunohistochemically identifiable REP-1
To confirm that the Ad.REP-1 is able to deliver REP-1 to cells lacking this protein, lymphoblasts and fibroblasts from individuals with CHM were exposed to this virus and evaluated for immunofluorescence evidence of REP-1 expression. Immunostaining was performed using antibody 2F1. High percentages of lymphoblasts and fibroblasts infected with the virus possessed immunohistochemically identifiable REP-1 (Fig. 2B, D ; $30% and 40%, respectively). Only background levels of fluorescence were detected in control Ad.LacZ-infected cells ( Fig. 2A,C) . Fibroblasts were infected more efficiently with recombinant adenovirus than lymphoblasts (compare 2B and D) and expressed REP-1 at higher levels. This was true for cells from patients with both the premature termination mutation and the deletion (data not shown). In both fibroblasts and lymphoblasts, REP-1 was localized to the cytosol.
Western analysis confirms that CHM cells exposed to Ad.REP-1 possess the REP-1 protein
Protein expression after infection of wildtype and CHM-affected human fibroblasts was analyzed by Western analysis as shown in Fig. 3 . Identity of REP-1 and REP-2 proteins was confirmed by probing with antibody J905, which recognizes REP-1 and REP-2 (lanes 1-4) and with antibody 2F1, which recognizes REP-1 only (lanes 5-7). As expected, REP-2 protein was identified in both CPF1 and CPF2 (lanes 2-4) regardless of treatment. As seen in lanes 2, 4, 5 and 7, infection of fibroblasts from both CPF1 and CPF2 with Ad.REP-1 results in production of REP-1 protein. The size of the REP-1 control protein (lane 1) is higher than that detected in the Ad.REP-1-treated fibroblasts due to presence of a ''his'' tag in the former. Treatment with Ad.REP-1 has minimal effect on levels of REP-2 (compare lanes 3 and 4). Treatment of fibroblasts with Ad.LacZ does not result in production of REP-1 (lanes 3, 6 and data not shown). Similar results were detected 3 . REP-1 is produced in fibroblasts from an individual with CHM after treatment with Ad.REP-1. Protein expression after infection of wildtype and CHM-affected human fibroblasts was analyzed by Western analysis. Identity of REP-1 and REP-2 proteins was confirmed by probing with antibody J905, which recognizes REP-1 and REP-2 (lanes 1-4) and with antibody 2F1, which recognizes REP-1 only (lanes 5-7). Total protein from fibroblasts from individual CPF2 was loaded in lanes 3, 4, 6 and 7 and from individual CPF1 in lanes 2 and 5. Protein was loaded after infection with Ad.REP-1 (lanes 4, 5, 7) or with Ad.LacZ (lanes 3 and 6). Lane 1 contains recombinant histagged REP-1. Infection with Ad.REP-1 results in production of REP-1 protein (lanes 2, 4) but has minimal effect on levels of REP-2 (compare lanes 3 and 4). Fig. 4 . REP-1 function is restored through treatment with Ad.REP-1. Rab GGTase activity was measured in extracts derived from fibroblasts from individual CPF2 as described under Section 2. Baseline levels of Rab GGTase activity are observed in control cells. Cells infected with Ad.REP-1 possessed high levels of Rab GGTase activity. in lymphoblasts (data not shown) but signal was much reduced, likely due to reduced infectability of these cells (see above).
REP-1 function is restored in defective cells through infection with Ad.REP-1
As shown in Fig. 4 , mock-infected fibroblasts from patient CPF2 had only baseline levels of Rab GGTase activity. In contrast, cells infected with Ad.REP-1 possessed high levels of Rab GGTase activity. The level of activity increased with the amount of total protein used in the assay. This demonstrates restoration of function of REP-1 to the defective cells.
Discussion
We have demonstrated that adenovirus-mediated delivery of REP-1 to fibroblasts and lymphoblasts of individuals with CHM results in rescue as measured immunohistochemically, through Western blot analysis and through functional assay. CHM is one of the few retinal diseases in which rescue can be evaluated initially in vitro using fibroblasts and lymphoblasts. The work presented here is the first step in developing gene-based therapies for CHM. Two ingredients must be made available before photoreceptor rescue can be attempted in vivo: (1) identity of the ocular cell types which normally express REP-1 and (2) an animal model for CHM. It will also be helpful to be able to test rescue in ocular tissue of carriers of and affected individuals with CHM. However, such tissue is rarely available.
Identity of the ocular cell type which normally expresses REP-1 is important as strategies must be developed which will specifically target these cells. Clinically, CHM is characterized by progressive degeneration of the RPE, choriocapillaris and retina. The degeneration causes a unique ophthalmoscopic appearance including RPE changes and choroidal atrophy, confirmed by fluorescein angiography (see for example Forsythe et al., 1997) . These changes, which identify the RPE and choroid to clinicians as suspects in the search for disease pathogenesis, gave the disease its name.
The pathological changes observed clinically in CHM may, however, represent secondary sequelae of the disease process. This may be analogous to the situation with Stargardt disease, which was initially thought to be a disease of the RPE but is now known to originate in photoreceptors (Allikmets et al., 1997; . What we do know about the CHM disease process is limited. Histopathologic studies of CHM are rare and tissue from only one affected individual has been evaluated (Rodrigues et al., 1984) . In that person, an asymptomatic 19 year old, there was diffuse loss of RPE and choroid. Results from histological studies of female carriers suggest that the disease may originate in photoreceptors and/or RPE cells. Disease is patchy in the carriers, perhaps due to Lyonization of the X chromosome. The eye of one carrier showed areas with normal photoreceptors interspersed with areas with either absent photoreceptors or photoreceptors reduced in number and with shortened or absent outer segments, presumably due to random X chromosome inactivation. The RPE was abnormally thick and pigmented and had atrophic regions. The choroid was only abnormal in areas underlying abnormal photoreceptors (Flannery, Bird, Farber, Weleber, & Bok, 1990 ). An eye of another such female had alternating areas of RPE atrophy but normal retina and choroid (Krill, 1977) . In a third carrier, the primary abnormalities appeared to lie in photoreceptors. In those, outer segments over the entire retina were malformed and there were specific areas of degeneration leading to complete loss of photoreceptors (Ghosh, McCulloch, & Parker, 1988) . More recently, an immunohistochemical study in a carrier revealed presence of REP-1 protein in rod photoreceptors and this may have been present in other retinal cells as well (Syed et al., 2001) . In summary, it is difficult to identify the original disease-causing cells from these studies, but these appear most likely to be photoreceptors or RPE cells--not choroidal cells. Finally, molecular biological studies have also been performed in order to determine the tissue origin of the disease. The results complement those from histopathologic studies in suggesting that REP-1 is normally expressed in the neural retina in primates and perhaps at lower levels in the RPE and choroid (Bernstein & Wong, 1998; Cremers, van de Pol, van Kerkhoff, Wieringa, & Ropers, 1990b; Desnoyers, Anant, & Seabra, 1996) .
In order to expedite development of a treatment for CHM, it will be helpful to obtain an animal model. This will aid in identifying the disease-causing cells. It will also be critical for development of gene based strategies aimed at rescue. Recently, van den Hurk and colleagues reported development of a mouse model of CHM resulting from disruption of the REP-1 gene. While this animal model is not completely representative of the human condition (there is lethality in male embryos), heterozygous females and chimeras for the REP-1 mutation develop photoreceptor degeneration (van den Hurk et al., 1997) . The RPE and choroid remain intact. These findings provide convincing evidence that the REP-1 mutation results in photoreceptor degeneration and strong evidence that the disease originates in photoreceptors. If the mutant REP-1 gene causes photoreceptor disease, vectors such as adeno-associated virus or lentivirus may be effective at delivering a gene which will provide rescue. These vectors are highly efficient at targeting photoreceptors and lead to stable transgene expression (Auricchio et al., 2001; Bennett, Duan, Engelhardt, & Maguire, 1997; Bennett et al., 1999; Dudus et al., 1999; Zufferey, Nagy, Mandel, Naldini, & Trono, 1997) . If it becomes necessary to target RPE cells, it may be advisable to evaluate rescue using adenovirus-based vectors, or AAVs produced with specific capsid serotypes so as to more efficiently target this cell type (Auricchio et al., 2001; Bennett, Wilson, Sun, Forbes, & Maguire, 1994; Li et al., 1994) . Lentiviral vectors may also be efficacious (Auricchio et al., 2001) .
In summary, the results reported here describe rescue of defective fibroblasts and lymphoblasts from humans with CHM. This leads naturally to the question of whether such a treatment, tailored to ocular tissue, would be effective in preventing or slowing retinal degeneration in such patients. Given the progress in understanding the molecular bases and pathogenic mechanisms involved in this disease, we believe that this approach is very exciting and may lead to a viable treatment for the blinding disease, CHM.
